Genetics and molecular basis of human peroxisome biogenesis disorders  by Waterham, Hans R. & Ebberink, Merel S.
Biochimica et Biophysica Acta 1822 (2012) 1430–1441
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReview
Genetics and molecular basis of human peroxisome biogenesis disorders☆
Hans R. Waterham ⁎, Merel S. Ebberink
Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, The Netherlands☆ This article is part of a Special Issue entitled: Metabo
peroxisomes in Health and Disease.
⁎ Corresponding author at: Laboratory Genetic Metabo
Center, University of Amsterdam, Meibergdreef 9, 1105 A
Tel.: +31 20 5665958.
E-mail address: h.r.waterham@amc.nl (HR. Waterha
0925-4439/$ – see front matter © 2012 Elsevier B.V. Al
doi:10.1016/j.bbadis.2012.04.006a b s t r a c ta r t i c l e i n f oArticle history:
Received 13 February 2012
Received in revised form 30 March 2012
Accepted 11 April 2012
Available online 25 April 2012
Keywords:
Peroxisome biogenesis disorder
Zellweger syndrome spectrum
PEX genes
Peroxisome assembly
Genetic testingHuman peroxisome biogenesis disorders (PBDs) are a heterogeneous group of autosomal recessive disorders
comprised of two clinically distinct subtypes: the Zellweger syndrome spectrum (ZSS) disorders and
rhizomelic chondrodysplasia punctata (RCDP) type 1. PBDs are caused by defects in any of at least 14 differ-
ent PEX genes, which encode proteins involved in peroxisome assembly and proliferation. Thirteen of these
genes are associated with ZSS disorders. The genetic heterogeneity among PBDs and the inability to predict
from the biochemical and clinical phenotype of a patient with ZSS which of the currently known 13 PEX
genes is defective, has fostered the development of different strategies to identify the causative gene defects.
These include PEX cDNA transfection complementation assays followed by sequencing of the thus identiﬁed
PEX genes, and a PEX gene screen in which the most frequently mutated exons of the different PEX genes are
analyzed. The beneﬁts of DNA testing for PBDs include carrier testing of relatives, early prenatal testing or
preimplantation genetic diagnosis in families with a recurrence risk for ZSS disorders, and insight in geno-
type–phenotype correlations, which may eventually assist to improve patient management. In this review
we describe the current status of genetic analysis and the molecular basis of PBDs. This article is part of a Spe-
cial Issue entitled: Metabolic Functions and Biogenesis of peroxisomes in Health and Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Peroxisomes are single-membrane bound organelles with a
protein-rich matrix, that are present in virtually all eukaryotic cells
and organisms ranging from unicellular yeasts to multicellular mam-
mals including humans. Peroxisomes are dynamic organelles that are
able to adjust their number and protein content in response to meta-
bolic needs and physiological conditions. Consequently, the number
of peroxisomes in human cells may range from 100 to more than
1000 per cell and they are most abundant in liver and kidney tubular
cells. The half-life of peroxisomes in cultured skin ﬁbroblast cells is
approximately two days [1].
Peroxisomesplay an important role in a number of essentialmetabolic
pathways, including, in humans, the biosynthesis of ether phospholipids
and bile acids, theα- andβ-oxidation of fatty acids, and the detoxiﬁcation
of glyoxylate and of reactive oxygen species generated in peroxisomes,
i.e. hydrogen peroxide and superoxide [2,3]. It is estimated that mam-
malian peroxisomes harbor more than 50 different enzyme activities,
some of which are tissue-speciﬁc while others are shared with other
subcellular compartments including mitochondria [3].lic Functions and Biogenesis of
lic Diseases, Academic Medical
Z Amsterdam, The Netherlands.
m).
l rights reserved.Given the central role of peroxisomes in human metabolism, it is
not surprising that defects in genes encoding peroxisomal proteins
result in a variety of different, often severe disorders. In fact, the bio-
chemical and genetic elucidation and characterization of such disorders
have been instrumental for our current understanding of peroxisome
biology, biochemistry and genetics [4–8]. Peroxisomal disorders can
be classiﬁed into two groups, including (a) the single peroxisomal en-
zyme deﬁciencies and (b) the peroxisome biogenesis disorders (PBDs)
[3,5,6]. In this review we will focus on the molecular basis of PBDs.
2. Clinical aspects of PBDs
The PBDs consist of two distinct subtypes: the Zellweger syn-
drome spectrum (ZSS) disorders and rhizomelic chondrodysplasia
punctata (RCDP) type 1. RCDP type 1 is clinically clearly distinct
from the ZSS disorders and characterized by proximal shortening of
the limbs (rhizomelia), multiple punctuate epiphyseal calciﬁcation
(chondrodysplasia punctata), cataracts, facial dysmorphism, micro-
cephaly, small stature, and psychomotor retardation [9]. RCDP type
1 is indistinguishable from RCDP type 2 and RCDP type 3, which
both are single peroxisomal enzyme deﬁciencies due to isolated
defects of respectively dihydroxyacetone phosphate acyl transferase
(DHAPAT/GNPAT) and alkyl-DHAP synthase, two peroxisomal matrix
enzymes involved in plasmalogen biosynthesis. Alkyl-DHAP synthase
is not imported into peroxisomes in RCDP type 1 cells, indicating that
the clinical phenotype of RCDP type 1 is primarily a consequence of a
disturbed plasmalogen synthesis [10–14].
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lapping clinical phenotypes: the cerebrohepatorenal syndrome or
Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD),
and infantile Refsum disease (IRD) [7,8]. Although originally de-
scribed as separate clinical entities they are now considered different
presentations within the same clinical and biochemical continuum
with ZS being the most and IRD the least severe. Patients who based
on clinical presentation belong to the severe side of the continuum
(ranging from ZS to NALD) usually come to clinical attention in the
newborn period, while patients with an IRD presentation are often
recognized later in childhood.
Infants with the most severe ZS presentation usually die during
the ﬁrst year of life, often without having made any developmental
progress. ZS classically presents with severe hypotonia and character-
istic craniofacial features including a large anterior fontanel, a prom-
inent forehead, shallow orbital ridges, epicanthal folds, a high arched
palate, a broad nasal bridge and a small nose with anteverted nares.
Ocular abnormalities such as cataracts, glaucoma and corneal
clouding are common. In addition, patients with ZS show seizures,
renal cysts and hepatic dysfunction, evident as neonatal jaundice
and elevation in liver function tests. In some severe patients calciﬁc
stippling (chondrodysplasia punctata) of the patellae and other long
bones may occur [7,8,15].
The clinical course of patients with the NALD and IRD presentation
is variable and may include developmental delay, hypotonia, liver
dysfunction, sensorineural hearing loss, retinal dystrophy and vision
impairment [16]. Children with the NALD presentation may reach
their teens, while patients with the IRD presentationmay reach adult-
hood [17]. The clinical conditions are often slowly progressive in par-
ticular with respect to loss of hearing and vision.
With the availability of genetic testing for the genes involved in
PBDs, several patients have been diagnosed at later ages. These
patients often present with predominantly sensory deﬁcits, including
loss of hearing and vision, but may also present with isolated ataxia
(see below).
Recently, the ﬁrst case of a different subclass of PBDs not associat-
ed with PEX genes was reported affecting the division of peroxisomes.
The reported female showed mild dysmorphic facial features, truncal
hypotonia, absent tendon reﬂexes, microcephaly, optic atrophy, fail-
ure to thrive, and severe developmental delay and died one month
after birth [18]. In addition to a peroxisomal ﬁssion defect the patientTable 1
PEX genes and encoded peroxins associated with peroxisome biogenesis disorders.
Gene Locus Exons Size
(kB)
cDNA
(kb)
Protein
(amino acids)
Protein
size (kDa)
D
PEX1 7q21.2 24 41.5 4.3 1283 142.9 C
p
PEX2 8q21.1 4 24.8 4.4 305 34.8 P
u
PEX3 6q24.2 12 39 2.0 373 42.1 P
PEX5 12p13.31 16 29.9 3.2/3.3 631/654 69.8/72.3 C
P
PEX6 6p21.1 17 15.1 3.2 980 104 C
P
PEX7 6q21-q22.2 10 91 1.5 323 35.9 C
PEX10 1p36.32 6 7.8 1 326/346 37/39.2 P
u
PEX11β 1q21.1 4 7.4 1.6 259 28.4 P
p
PEX12 17q12 3 3.8 2.6 359 40.8 P
u
PEX13 2p14-p16 4 31.2 1.4 403 44.1 P
PEX14 1p36.22 9 155.8 1.9 377 41.2 P
PEX16 11p11.2 11 8.4 1.7 336/346 38.6/39.3 P
PEX19 1q22 8 8.3 0.9 299/209 32.8/23.3 C
PEX26 22q11.21 6 11 0.9 305 33.9 Pshowed a profound defect in the ﬁssion of mitochondria the conse-
quences of which were most probably more severe than of the perox-
isomal ﬁssion defect.
3. Biochemical aspects of PBDs
Cells of patients with a PBD are characterized by the deﬁciency of
functional peroxisomes. Cells from patients with the severe ZS pre-
sentation entirely lack intact organelles, although peroxisomal mem-
brane remnants are often still present. Cells frommilder patients may
still contain a lower number of intact functional peroxisomes or show
peroxisomal mosaicism., i.e. some cells still contain intact functional
peroxisomes while others do not [19,20].
Because most peroxisomal enzymes are unstable in the cytosol
and rapidly degraded, the absence of intact functional peroxisomes
has major consequences for most of the metabolic pathways in
which peroxisomes are involved. This is evident from the biochemical
aberrations observed in PBD patients, which range from the accumu-
lation of substrates normally metabolized by peroxisomes (e.g. very-
long-chain fatty acids (VLCFAs), pristanic acid, phytanic acid,
dihydroxycholestanoic acid (DHCA), trihydroxycholestanoic acid
(THCA)) to a shortage of end products of peroxisomal metabolism
(e.g. plasmalogens, cholic and chenodeoxycholic acid, docosahexaenoic
acid) [3,5,6,8].
The clinical diagnosis of a PBD can be deﬁnitively conﬁrmed by
biochemical laboratory assays. Measurement of plasma VLCFA levels
is commonly used as a ﬁrst informative test [3,5,6]. Elevation of the
VLCFA cerotic acid (C26:0) and the ratio C26:0 to docosanoic acid
(C22:0) is consistent with a defect in peroxisomal fatty acid metabo-
lism. Additional test ﬁndings that are consistent with a PBD are ele-
vated plasma levels of phytanic acid, pristanic acid, pipecolic acid
and the bile acid precursors THCA and DHCA, and lowered concentra-
tions of C16 and C18 plasmalogen levels in erythrocytes [3,5,6].
Ideally, the analyses in plasma samples are followed by studies in
primary skin ﬁbroblasts, which involve 1) determination of the VLCFA
levels; 2) evaluation of the capacity of the cells to perform peroxi-
somal C26:0 and pristanic acid β-oxidation; 3) evaluation of the
capacity of the cells to perform peroxisomal phytanic acid α-
oxidation; 4) analysis of the activity of dihydroxyacetonephosphate
acyltransferase; and 5) catalase immunoﬂuorescence (IF) microscopy
to assess the absence or phenotype of peroxisomes in the cells [3,5,6].escription and function
ytosolic AAA protein (ATPase associated with diverse cellular activities),
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eroxisomal membrane protein, ring-ﬁnger protein, part of PEX2–PEX10–PEX12
biquitin ligase complex.
eroxisomal membrane protein, docking protein for PEX19p.
ytosolic receptor protein for PTS1-targeted matrix proteins. Long form mediates
TS1 and PTS2 import; short form only PTS1 import.
ytosolic AAA protein (ATPase associated with diverse cellular activities), part of
EX1–PEX6–PEX26 export complex.
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Fig. 1. Somatic cell fusion complementation assay. A. Principle of the polyethylene gly-
col (PEG)-induced somatic cell fusion complementation assay previously used to as-
sign cultured cells from ZSS patients to different genetic complementation groups. B
and C. Examples of multi-nuclei-containing hybrid cells processed for IF microscopy
using antibodies against catalase. In panel B no genetic complementation occurs,
whereas in panel C genetic complementation occurs as indicated by the punctated
ﬂuorescent staining of peroxisomes.
1432 HR. Waterham, MS. Ebberink / Biochimica et Biophysica Acta 1822 (2012) 1430–14414. Molecular basis of PBDs
The PBDs are autosomal recessive disorders and can be caused by
a defect in any of at least 14 different PEX genes (Table 1). These PEX
genes encode proteins named peroxins (denoted here as PEX) that
are involved in various stages of peroxisomal protein import and/or
the biogenesis of peroxisomes.
Patients affected with RCDP type 1 have mutations in the PEX7
gene, which encodes a cytosolic receptor protein that recognizes
newly synthesized peroxisomal matrix enzyme precursors containing
a peroxisomal targeting signal type 2 and directs these to peroxi-
somes [5,10,21–23]. Mutations in PEX7 result in defective peroxisom-
al import of only a small subset of peroxisomal enzymes, which
causes a biochemical, cellular, and clinical phenotype that is clearly
distinct from the ZSS disorders.
The remaining 13 PEX genes each result clinically in a ZSS disorder
when defective. Already prior to the actual identiﬁcation of the ﬁrst
human PEX genes, it had become clear from functional complementa-
tion studies with patient cells that PBDs are genetically heteroge-
neous. These complementation studies involved polyethylene glycol
(PEG)-induced cell fusion of cultured ﬁbroblasts from different PBD
patients [6,24–26], followed by microscopical assessment of the per-
oxisomal presence using antibodies against the peroxisomal matrix
enzyme catalase (Fig. 1). When both patient cells have a defect in
the same PEX gene, peroxisomes are not formed and catalase will re-
main in the cytosol. When the patient cells have defects in different
PEX genes, however, peroxisomes are formed resulting in a punctated
ﬂuorescent pattern. These complementation studies revealed 12 dif-
ferent genetic complementation groups indicating that peroxisome
biogenesis in humans requires at least 12 different genes in addition
to the PEX7 gene defective in RCDP type 1. Most of the corresponding
human PEX genes were subsequently identiﬁed in silico on the basis
of sequence similarity with yeast PEX genes identiﬁed by functional
complementation of peroxisome-deﬁcient yeast mutants [9]. Two
genes, PEX2 and PEX26, were identiﬁed by complementation of
peroxisome-deﬁcient CHO cells [27,28].
At present more than 30 different PEX genes have been identiﬁed
in different yeast species. The peroxins encoded by these PEX genes
are involved in different peroxisomal processes, such as the formation
of peroxisomal membranes, peroxisomal growth, ﬁssion and prolifer-
ation, and import of matrix proteins [29]. Of these yeast peroxins, 19
have been implicated in the process of peroxisome protein import
and organelle assembly, whereas in humans, so far only 13 peroxins
have been identiﬁed that are required for these processes. A number
of additional proteins have been identiﬁed that are involved in the
proliferation and division of peroxisomes, including PEX11β which
very recently was found defective in a patient presenting with a
mild ZSS-like phenotype [30].
There is currently no evidence that defects in additional PEX genes
can cause ZSS disorders. In a recent study aimed at ﬁnding additional
genetic complementation groups, peroxisome-deﬁcient ﬁbroblast cell
lines from more than 600 affected ZSS patients were assigned to ge-
netic complementation groups using a PEX cDNA transfection com-
plementation assay speciﬁcally developed for this purpose and
discussed below [31]. Surprisingly, all cells could be assigned to the
previously deﬁned genetic complementation groups, which suggested
that only mutations in the 12 corresponding PEX genes would lead to
peroxisome deﬁciency. It cannot be excluded, however, that mutations
in other (PEX) genes do not result in peroxisome deﬁciency and cause
milder or different biochemical and clinical phenotypes, as indeed was
recently found for the PEX11β gene [30].
5. Peroxisome biogenesis
The biogenesis of peroxisomes involves a series of different pro-
cesses including the formation of peroxisomal membranes, importof peroxisomal membrane and matrix proteins, peroxisomal growth,
division and proliferation.5.1. Peroxisome assembly and peroxisomal protein import
Peroxisomes do not contain DNA and all proteins required for the
assembly and function of peroxisomes are encoded by nuclear genes
and synthesized on free polyribosomes in the cytosol after which
they are transported to peroxisomes. The molecular mechanisms
involved in the transport and import of peroxisomal proteins are
largely resolved, also because most key proteins (i.e. peroxins) that
take part in these processes are encoded by one of the PEX genes
found to be defective in cells from PBD patients. We will only brieﬂy
summarize the principles of these processes with emphasis on the
role of the different peroxins therein (see also Fig. 2).
The transport of peroxisomal matrix proteins to peroxisomes is
highly selective and mediated by speciﬁc import sequences known
as peroxisomal targeting sequences (PTSs). The majority of peroxi-
somal proteins destined for the matrix contain a C-terminal peroxi-
somal targeting sequence PTS1, a tripeptide with consensus sequence
(S/A/C)-(K/H/R)-(L/M) [32]. A small subset of matrix proteins contains
an internal peroxisomal targeting sequence PTS2, an octapeptide with
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the N-terminus of the protein [33].
Newly synthesized matrix proteins destined for peroxisomes are
recognized and bound in the cytosol by speciﬁc cytosolic receptor
proteins, which subsequently direct them to the peroxisomal mem-
brane. Newly synthesized proteins containing a PTS1 are recognized
and bound by the cytosolic receptor PEX5, while proteins containing
a PTS2 are recognized and bound by the cytosolic receptor PEX7. In
humans, two functional isoforms of PEX5 have been identiﬁed
encoded by the same PEX5 gene and synthesized as a result of alter-
native splicing [34]. Both the shorter (PEX5S) and the longer form
(PEX5L) can bind PTS1 proteins and direct these to the peroxisomal
membrane. In addition, PEX5L contains a PEX7-binding domain re-
quired for binding and subsequent directing matrix protein-loaded
PEX7 to the peroxisomal membrane [34–36]. The matrix protein-
loaded receptor proteins dock onto the peroxisomal docking complex
constituted by the peroxisomal membrane proteins PEX14 and
PEX13. After docking, the matrix protein will be translocated across
the peroxisomal membrane into the peroxisomal lumen and the
receptor proteins will be released from the peroxisomal membrane
for another import cycle [37,38]. These latter two steps of the cycle
require the action of the peroxisomal membrane proteins PEX2,
PEX10 and PEX12, which all three are zinc-binding RING ﬁnger pro-
teins that belong to the protein family of ubiquitin ligases. PEX2,
PEX10 and PEX12 catalyze either the mono- or the poly-ubiquitination
of PEX5. Mono-ubiquitination will promote the recycling of PEX5
while the poly-ubiquitination makes PEX5 a substrate for proteasome-
mediated degradation [37,39–41].
The cytosolic proteins PEX1 and PEX6 interact with each other, are
anchored to the peroxisomal membrane via the peroxisomal mem-
brane protein PEX26 and are involved in the release of ubiquitinated
PEX5 from the peroxisomal membrane [42,43].
As follows from the proposed functions of the encoded peroxins,
mutations in the PEX1, PEX2, PEX5, PEX6, PEX10, PEX12, PEX13,
PEX14, PEX26 genes typically affect only the import of peroxisomal
matrix proteins. Cells from PBD patients with defects in these genes
still contain peroxisomal membrane remnants containing peroxisom-
al membrane proteins. Cells from patients with mutations in the PEX7
gene only display a defect in the import of PTS2-targeted peroxisomal
matrix proteins, resulting in a distinct biochemical and clinical phe-
notype (RCDP type 1, see above).
A similar but less well characterized cycle has been proposed for
the transport and membrane incorporation of peroxisomal mem-
brane proteins (PMPs; Fig. 2). These proteins also contain speciﬁc in-
ternal targeting sequences [44] that are recognized by the cytosolic
PEX19 protein, which docks onto the peroxisomal membrane protein
PEX3 in the peroxisomal membrane [45,46]. PEX3 is one of the earli-
est membrane proteins found in peroxisomal membranes and its
incorporation is independent from PEX19 [47]. The peroxisomal
membrane protein PEX16 is known to interact with PEX3, but its
exact role in the import of peroxisomal membrane proteins is unclear
[47].
The involvement of PEX3, PEX16 and PEX19 in the transport and
incorporation of peroxisomal membrane proteins also follows from
the observation that severe mutations in the PEX3, PEX16 and PEX19
genes affect the import of both peroxisomal matrix and membrane
proteins; cells with defects in these genes are completely devoid of
any peroxisomal remnants [48–51]. It should be noted, however,
that mild mutations in the PEX16 and PEX3 genes may result in a
less severe phenotype with lower numbers of (enlarged) peroxi-
somes [52].
5.2. Proliferation and division of peroxisomes
Recent data indicate that new peroxisomes are predominantly
formed by growth and division of pre-existing peroxisomes [1,53],but that they can also arise de novo from preperoxisomal vesicles
that originate from specialized compartments of the endoplasmic
reticulum (ER) [54]. These preperoxisomal vesicles develop into
mature, metabolically active peroxisomes through the import of
peroxisomal membrane proteins and subsequently matrix proteins.
Different proteins have been identiﬁed that are involved in the
proliferation and division of peroxisomes. The division of peroxi-
somes involves three distinct sequential steps: elongation of peroxi-
somes, membrane constriction, and ﬁnally ﬁssion of peroxisomes
[55–57]. The following proteins are involved in the ﬁssion of peroxi-
somes: Dynamin-Like Protein 1 (DLP1 or DRP1) [18,58], mammalian
Fission 1 (hFIS1) [59,60] and mammalian Mitochondrial Fission
Factor (Mff) [61]. Remarkably, these three proteins do not only play
a role in the ﬁssion of peroxisomes but also in the ﬁssion of mitochon-
dria. PEX11 proteins are involved in the elongation of peroxisomes. In
mammals, including humans, three different PEX11 isoforms have
been identiﬁed encoded by separate genes: PEX11α, PEX11β and
PEX11γ [62,63]. Overexpression of PEX11α and PEX11β in mammali-
an cells results in an increase in peroxisome number, but PEX11γ
overexpression does not have an effect on peroxisome abundance
[64].
Currently, only two patients have been identiﬁed with a different
defect in any of the proteins known to be involved in the proliferation
and division of peroxisomes. The ﬁrst reported patient was a severely
affected female patient, who died one month after birth and post-
mortally was found to have a dominant-negative heterozygous muta-
tion in the DLP1 gene, which resulted in a severe ﬁssion defect of both
peroxisomes and mitochondria [18].
Very recently, we identiﬁed the ﬁrst patient with a complete deﬁ-
ciency of PEX11β due to a homozygous nonsense mutation in the
encoding gene. The male patient presented with a ZSS-like disorder,
including mild intellectual disability, progressive hearing loss, and
sensory nerve involvement. Remarkably, although microscopical in-
vestigations of the patient's ﬁbroblasts indicated a clear defect in per-
oxisome division, all standard biochemical peroxisomal parameters in
plasma, erythrocytes and ﬁbroblasts were normal [30].
6. Genetics of PBDs
When we combine published data with the partly unpublished
data from our laboratory, the defective PEX genes of more than
1300 unrelated PBD patients have been identiﬁed by complementa-
tion testing with patient cells and/or sequence analysis (Table 2).
This includes 231 patients with a defect in the PEX7 gene, resulting
in the clinically distinct RCDP type 1. For the majority of ZSS patients,
the pathogenic mutations have been determined by sequencing of the
implicated PEX genes providing a comprehensive overview of the fre-
quency distribution of the different PEX gene defects and associated
mutations. For a detailed listing of presently known mutations we
refer to the PEX gene database dbPEX (http://www.dbpex.org),
which provides a current update and statistics of published and
unpublished mutations in the different PEX genes. Here we will only
brieﬂy discuss the different PEX genes, the PEX gene defect frequen-
cies and the most common mutations found in the PEX genes.
6.1. PEX1
Among all diagnosed patients with a ZSS disorder almost 60% have
mutations in the PEX1 gene. PEX1 encodes a 143-kDa cytosolic protein
that belongs to the AAA ATPase protein family (ATPases Associated
with various cellular Activities) and contains two highly conserved
domains of 230 amino acids, which contain ATP-binding Walker A
and B motifs and have ATPase activity [40,65]. At present, 90 different
mutations have been identiﬁed in the PEX1 gene, including 23 mis-
sense, 15 nonsense, 30 deletion, 11 insertion, 7 splice site, 2 indel mu-
tations and 2 disruptions of the start codon [31]. Mutations are
Fig. 2. Import machinery for peroxisomal protein import. Schematic presentation of the human import machinery for peroxisomal matrix and membrane proteins indicating the
different roles of the 13 different peroxins. For details see main text.
Table 2
Frequency distribution of PEX gene defects among 1308 patients diagnosed with a
peroxisome biogenesis disorder based on published and own unpublished data.
PEX gene Number of
patients
identiﬁed
Genetically
analyzed
patients
Frequency (%)
among PBDs
Frequency (%)
among ZSS
disorders
PEX1 634 384 48.5 58.9
PEX2 42 42 3.2 3.9
PEX3 6 6 0.5 0.5
PEX5 18 18 1.4 1.7
PEX6 171 154 13.1 15.9
PEX7 231 231 17.7 –
PEX10 45 42 3.4 4.2
PEX11β 1 1 b0.1 b0.1
PEX12 77 66 5.9 7.1
PEX13 18 18 1.4 1.7
PEX14 3 3 0.2 0.3
PEX16 14 14 1.0 1.2
PEX19 4 4 0.3 0.4
PEX26 45 39 3.4 4.2
Total 1308 1021 100 100
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most mutations. By far the most commonmutation in PEX1 is the mis-
sense mutation c.2528G>A, which changes the glycine located in the
second ATP-binding domain at amino acid position 843 into an
aspartic acid (p.G843D). This mutation reduces the binding between
PEX1 and PEX6 [66,67]. The effect of the mutation is relatively mild
and cells of patients with a p.G843D mutation in the PEX1 gene
often display peroxisomal mosaicism when cultured at 37 °C. This
peroxisomal mosaicism is temperature sensitive, meaning that
when ﬁbroblasts of patients homozygous for p.G843D are cultured
at 30 °C, peroxisomes regain the ability to import catalase and other
peroxisomal matrix proteins and the various peroxisomal metabolic
functions normalize. In contrast, when cultured at higher tempera-
tures, peroxisomes become deﬁcient and the phenotype becomes
worse [66,68]. The second most common mutation in PEX1 is
c.2097_2098insT (or c.2097dup), which results in a frame shift theo-
retically predicted to cause a truncated PEX1 protein [69]. Northern
blot analysis indicated that this mutation results in low steady state
PEX1 mRNA levels, implying that the mRNA produced is targeted for
nonsense mediated decay. Patients homozygous for this mutation
are invariably affected with the severe ZS phenotype. About 80% of
the patients with mutations in the PEX1 gene are at least heterozy-
gous for one of these two common mutations [31,67,69–72].
6.2. PEX2
The PEX2 gene was the ﬁrst identiﬁed PEX gene and contains four
exons, although the entire coding region is included in exon 4 [28].
PEX2 is an integral peroxisomal membrane protein of 35 kDa with
two transmembrane domains and a zinc-binding motif, probably in-
volved in the poly-ubiquitination of the peroxisomal import recep-
tor PEX5 [41]. So far 17 different mutations have been identiﬁed in
exon 4 of the PEX2 gene, including 4 missense, 5 nonsense, 6 dele-
tion and 2 insertion mutations [31]. The most common mutation
in the PEX2 gene is c.355C>T, which changes the arginine located
at amino acid position 119 into a stop codon (p.R119X). Although
this mutation results in a truncated PEX2 protein lacking the zinc-
binding domain, it is associated with temperature sensitivity: pa-
tient cells cultured at 30 °C show partial catalase import [73]. Alsopatient ﬁbroblasts homozygous for the second common mutation
c.669G>A (p.Trp223X) display a mosaic peroxisomal pattern when
cultured at 37 °C [74,75].6.3. PEX3
PEX3 is an integral peroxisomal membrane protein of 42 kDa
with two putative membrane-spanning domains and its C-
terminus exposed to the cytosol. The exact function of PEX3 is
unclear, but it is assumed that PEX3 functions as the docking protein
for the PEX19-PMP complex on the peroxisomal membrane and
plays a role in the insertion of peroxisomal membrane proteins
into the peroxisomal membrane [76–78]. A complete deﬁciency of
PEX3 causes the absence of peroxisomal remnants (ghosts) in pa-
tient cell lines. In total, six different mutations in PEX3 have been
reported, including 2 nonsense, 2 deletion, 1 insertion and 1 splice
site mutation [31]. The six known PEX3-defective patient cell lines
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ent exons [31,50,51,79,80].6.4. PEX5
PEX5 is a 70-kDa protein with seven di-aromatic pentapeptide re-
peats (WxxxF/Y) in its N-terminal half and seven tetratricopeptide
repeats (TPRs) in its C-terminal half [34,81]. As discussed above, in
humans, two functional protein variants of PEX5, PEX5S and PEX5L
are produced as a result of alternative splicing of the PEX5 mRNA.
The longest variant, PEX5L, contains an additional 111 bp encoding
37 amino acids, due to alternative splicing of exon 7 [34]. Eleven dif-
ferent mutations in PEX5 have been identiﬁed, including 3 missense, 4
nonsense, 1 indel, and 2 splice site mutations [82]. Mutations are dis-
tributed across the entire gene, although exons 12 and 14 harbor
most mutations [82]. The most common mutation c.1578T>G
(p.N526K) results in an isolated PTS1 protein import defect [82].6.5. PEX6
The PEX6 gene encodes a 104-kDa protein, which is a member of
the AAA ATPase family and interacts with PEX1 [65]. Mutations in
the PEX6 gene are the second most common cause for ZSS disorders
(approximately 16%; Table 2). At present 104 different mutations
have been reported in the PEX6 gene, which are scattered throughout
the entire PEX6 gene, although one-third of mutations are found in
exon 1 [83]. Among the 106 mutations, 37 missense, 5 nonsense, 32
deletion, 9 insertion, 1 indel and 20 splice site mutations have been
identiﬁed. Althoughmanymutations are found in exon 1, themost com-
mon mutation in PEX6 is a small deletion, c.1314_1321delGGAGGCCT,
located in exon 5.6.6. PEX7
The PEX7 gene encodes the cytosolic receptor protein required for
the import of PTS2-targeted peroxisomal matrix proteins. The 36-kDa
protein contains six series of WD40 repeats [84]. A defect in PEX7 is
the cause of RCDP type 1, which is the underlying defect in approxi-
mately 18% of the patients with a PBD but clearly distinctive from
the ZSS disorders. At present, 38 different mutations have been iden-
tiﬁed in the PEX7 gene, including 14 missense, 7 nonsense, 6 deletion,
4 insertion and 7 splice site mutations. Mutations are distributed
across the entire gene, although exons 1 and 9 harbor most mutations
[21,22]. The nonsense mutation c.875T>A (p.L292X) is by far the
most common PEX7 mutation and is due to a founder effect [85].6.7. PEX10
PEX10 is a 37-kDa integral peroxisomal membrane protein, which
contains two transmembrane domains and a C-terminal zinc-binding
motif, similar as PEX2 and PEX12. Two mRNA splice forms of PEX10
have been identiﬁed in skin ﬁbroblasts, resulting from the use of a dif-
ferent splice acceptor site at the 3′ end of intron 3. The longer form
accounts for 10% of the PEX10 mRNA in the cell and appears to be
slightly less functional [86]. So far, 30 different mutations have been
identiﬁed in the PEX10 gene, including 13 missense, 6 nonsense, 5 de-
letion, 2 insertion, 1 splice site mutation and 3 disruptions of the start
codon [31]. Mutations are distributed across the entire gene, but exon
5 harbors most mutations. The most common PEX10 mutation is
c.814_815delCT, which is found mainly in the Japanese population
[87]. The second most common mutation is the c.704_705insA
leading to a truncated protein missing the zinc binding motif [88].6.8. PEX11β
PEX11β is a 28.5-kDa integral peroxisomal membrane protein,
andmember of the PEX11 protein family, which in mammals includes
three different isoforms encoded by separate genes: PEX11α, PEX11β
and PEX11γ [62,63]. PEX11 proteins are involved in the elongation
of peroxisomes, which is part of peroxisome division. A defect in
PEX11β was reported only very recently in one patient with a mild
ZSS-like presentation, who was homozygous for a nonsense mutation,
c.64C>T (p.Q22X), as a consequence of which no PEX11β protein is
produced [30].
6.9. PEX12
Mutations in the PEX12 gene are the third common cause of a ZSS
disorder: 7% of the reported patients with a ZSS disorder have muta-
tions in PEX12 (Table 2). The 41-kDa PEX12 protein is, like PEX2 and
PEX10, one of the RING (abbreviation for ‘really interesting new
gene’) ﬁnger proteins; it contains two transmembrane domains and
a C-terminal zinc-binding motif [89–91]. Currently 36 different muta-
tions have been identiﬁed in the PEX12 gene, including 7 missense, 6
nonsense, 15 deletion, 6 insertion and 2 splice site mutations [31].
Mutations are distributed across the entire gene, although exons 2
and 3 harbor most mutations. The most common PEX12 mutation,
c.959C>T (p.S320F) is located in the zinc-binding domain and pre-
dominantly found in patients from Turkish descent. Patients homozy-
gous for this mutation present with an atypical mild biochemical
phenotype in cultured ﬁbroblasts: the biochemical peroxisomal
parameters are mostly normal to slightly abnormal. The mutation
causes a temperature-sensitive phenotype in cells: when cultured at
37 °C, 70% of the cells contain catalase-positive peroxisomes, when
cultured at 30 °C, all cells contain catalase import competent peroxi-
somes [92]. The c.126+1G>T is the second common PEX12 mutation
and causes aberrant splicing of PEX12.
6.10. PEX13
PEX13 is a 44-kDa peroxisomal transmembrane protein, which
contains a transmembrane domain as well as an Src homology 3
(SH3) domain [93] and interacts with PEX14. Currently 10 different
mutations have been reported in the PEX13 gene, including 3 mis-
sense, 3 nonsense, 3 deletions, and 1 splice site mutation [31]. Most
of the identiﬁed mutations are located in exon 2 or 4, but no common
mutations have been found [94–97].
6.11. PEX14
The PEX14 gene encodes a 41-kDa peroxisomal membrane pro-
tein. PEX14 interacts with PEX13 and forms the peroxisomal docking
site for the PTS1 receptor PEX5 [98]. A mutation in PEX14 is one of the
least common causes of a ZZS disorder; so far only 3 different muta-
tions have been identiﬁed, including 1 missense, 1 deletion and 1
splice site mutation [31,99,100].
6.12. PEX16
The PEX16 gene encodes a 39-kDa integral peroxisomal mem-
brane protein with two putative membrane-spanning domains and
its C- and N-terminal domains exposed to the cytosol. Two different
mRNA variants of PEX16 are produced as a result of alternative splic-
ing, each with an alternate exon 11 (exon 11a and exon 11b). Both
transcription variants are expressed in human ﬁbroblasts, but the
variant containing exon 11a is most abundant. Two groups of
PEX16-defective patients have been reported; patients with a severe
clinical presentation of whom the ﬁbroblasts displayed a defect in
the import of both peroxisomal matrix and membrane proteins,
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and, more recently, several patients with a relatively mild clinical
phenotype of whom the ﬁbroblasts showed enlarged, import-
competent peroxisomes [52]. Currently, 10 different mutations have
been identiﬁed in the PEX16 gene, including 2 missense, 1 nonsense,
3 deletions, 1 insertions and 1 splice site mutation [31]. Mutations
are localized across the entire gene. The mutations found in the
milder patients are located in the C-terminus of the protein.
6.13. PEX19
The PEX19 gene encodes a mainly cytosolic 30-kDa protein that
binds many peroxisomal membrane proteins, strongly suggesting
that PEX19 functions as the receptor for peroxisomal membrane pro-
teins [46,103]. Patients with a defect in PEX19 presented with a
severe ZS phenotype and the ﬁbroblasts displayed a total absence of
peroxisomal remnants [49]. 3 different mutations have been identi-
ﬁed in the PEX19 gene, including 1 nonsense, 1 deletion and 1 inser-
tion mutation [31]. The mutations are localized in exons 3 and 6. A
defect in PEX19 is one the least common causes of a ZSS disorder
(Table 2).
6.14. PEX26
The PEX26 gene encodes a 34-kDa peroxisomal membrane protein
with one putative membrane-spanning domain [104]. PEX26 inter-
acts with PEX1 and PEX6. Human PEX26 is the orthologue of yeast
PEX15. Twenty three different mutations have been identiﬁed in the
PEX26 gene, including 6 missense, 5 nonsense, 5 deletion, 3 insertion,
3 splice site mutations and 1 disruption of the start codon [31]. Muta-
tions are distributed across the entire gene, although exons 2 and 3
harbor most mutations. The most common mutation is c.292C>T
(p.R98W), which results in a temperature-sensitive biochemical phe-
notype [27,104].
7. Genetic diagnosis of PBDs
Because it is not possible to predict from the biochemical and clin-
ical phenotype of a patient with ZSS which of the currently known 13
PEX genes is defective, different approaches have been developed to
rapidly identify the affected gene, including PEX cDNA transfection
complementation assays followed by sequencing of the implicated
PEX gene, and a genetic PEX gene screen algorithm in which the
most frequently mutated exons of the different PEX genes are
analyzed.
The identiﬁcation of the defective PEX gene and the mutations
causing a PBD enables carrier testing of relatives and allows early pre-
natal testing or preimplantation genetic diagnosis in families with a
recurrence risk for ZSS disorders. In addition, the knowledge can be
used to determine genotype–phenotype correlations which may
delineate the effect of certain mutations and could eventually assist
to improve patient management.
7.1. PEX cDNA transfection complementation assay
The PEX cDNA transfection complementation assay developed in
our laboratory (Fig. 3) takes advantage of the known identities of
the 12 most common human PEX genes that can cause a ZSS disorder
(PEX11β not included) [31] and has replaced the above discussed
complementation analysis involving somatic cell hybridization. A
similar approach with some variations has been developed and
reported by Krause et al. [105]. In the assay developed and also
used for diagnostic purpose in our laboratory [31], peroxisome-
deﬁcient ZSS primary ﬁbroblast cells are co-transfected with a mam-
malian expression vector containing one of the 12 different PEX
cDNAs and a second vector that expresses Green Fluorescent Protein(eGFP) tagged with the peroxisomal targeting signal‐SKL, which al-
lows microscopical detection of peroxisomes when they are present.
Two to three days after transfection, cells are examined by means of
ﬂuorescence microscopy to determine the subcellular localization of
the peroxisomal reporter protein eGFP-SKL. A punctuate ﬂuorescent
pattern indicates the reappearance of peroxisomes and thus genetic
complementation, whereas a diffuse, cytosolic ﬂuorescent staining in-
dicates non-complementation. To identify the defective PEX gene, the
transfections of cell lines are performed in three subsequent series
based on the currently known frequency of the different PEX gene de-
fects (Table 2). In a ﬁrst series, cells are transfected separately with
PEX1, PEX6 and PEX12. Cells that are not functionally complemented
are then transfected separately with PEX2, PEX10 and PEX26 and ﬁnal-
ly with PEX5, PEX13 and PEX14. Transfection with PEX3, PEX16 and
PEX19 is performed when patient ﬁbroblasts show no peroxisomal
membrane remnants based on IF microscopy using antibodies against
a peroxisomal membrane protein, such as PMP70 or ALDP.
After the defective PEX gene is identiﬁed by complementation
testing, all exons plus ﬂanking intronic sequences of the PEX genes
are sequenced following ampliﬁcation of these by PCR from genomic
DNA isolated from the patient's cells [31].
Although the PEX cDNA transfection complementation assay has
turned out to be very efﬁcient, reliable and reproducible in the iden-
tiﬁcation of the defective PEX gene in ZSS patients it has a few draw-
backs. For example, it requires the availability of cultured ﬁbroblasts
from the patients. Moreover, the assay works only well for cells that
in majority display a complete peroxisome deﬁciency and for cell
lines displaying peroxisomal mosaicism that is sensitive to culturing
at 40 °C, which exacerbates the defect in peroxisome biogenesis
[19]. This implies that primarily cells from (more) severely affected
patients can be used. When patient ﬁbroblasts are not available or
do not display peroxisome deﬁciency after culturing at 40 °C, differ-
ent approaches will be required, such as sequential sequencing of
the 13 known PEX genes in an order based on the currently known
frequency of the different PEX gene defects.7.2. PEX gene screen algorithm
As an alternative to sequential sequencing of the entire PEX genes,
a PEX gene screen algorithm has been proposed, which involves sys-
tematic screening of selected exons of the six PEX genes that are
found most commonly defective in ZSS patients. Sequential sequence
analysis of exons 13, 15, and 18 of the PEX1 gene, exon 4 of the PEX2
gene, exon 1 of the PEX6 gene, exons 2 and 3 of the PEX12 gene, exons
3–5 of the PEX10 gene, and ﬁnally exons 2 and 3 of the PEX26 gene in
a cohort of 91 patients identiﬁed at least one pathogenic mutation in
72 cases, i.e. 79% [106]. Steinberg and colleagues proposed to use this
PEX gene screen algorithm as the ﬁrst in a three-step strategy. If the
PEX gene screen does not identify mutations in any of the analyzed
exons, they recommend subsequently analyzing ﬁrst the entire PEX1
and PEX6 genes, which in their cohort of 91 patients increased the
sensitivity to 92%. Eventually, patients remaining undeﬁned would
then be candidates for mutations in PEX3, PEX5, PEX11β, PEX13,
PEX14, PEX16, and PEX19 or in a PEX gene not yet associated with
human disease [106,107].
The PEX gene screen algorithm could be helpful in screening DNA
from patients for which no ﬁbroblasts are available, or whose cells do
not show a distinct peroxisome-deﬁcient phenotype and thus would
not be suitable for complementation testing. In addition, the ap-
proach could be helpful by screening parental DNAs in those cases
where no DNA is available from the index patient.
It is expected that in the near future the defective PEX genes in
patients will be identiﬁed by whole exome sequencing or other next
generation sequencing technologies that are rapidly evolving and
becoming cost-effective.
Fig. 3. PEX cDNA transfection complementation assay. A. Principle of PEX cDNA trans-
fection complementation assay used to identify the defective PEX gene in cells from
ZSS patients. B and C. Examples of cells cotransfected with a PEXx-containing expres-
sion plasmid and a plasmid expressing the peroxisomal reporter protein GFP-SKL. In
panel B genetic complementation occurs as indicated by the punctated ﬂuorescent
staining of peroxisomes, whereas in panel C no genetic complementation occurs, and
the reporter protein is localized in the cytosol.
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The identiﬁcation of the defective PEX gene and pathogenic mu-
tations causing a PBD makes carrier testing possible in families of
affected patients as well as more distant relatives. To this end,
relatives are ﬁrst analyzed for the presence of the familial mutation
in the known PEX gene. If that is the case, the entire PEX gene of
the partner can be sequenced to determine or exclude the presence
of any potential pathogenic mutation. In the vast majority of cases
no mutation will be identiﬁed in the partner's PEX gene, which
does not per se exclude but signiﬁcantly lowers the chance of car-
riership and, accordingly, the chance on diseased progeny. It should
be noted that carriers for PBD cannot be identiﬁed by biochemical
testing.
The poor outcome and often early death associated with PBDs
makes prenatal and preimplantation diagnosis an important service
for families with previously affected children. Prenatal diagnosis for
a PBD can be performed by biochemical as well as genetic testing
and is carried out using chorionic villus samples, cultured chorionic
villus cells, cultured amniotic ﬂuid cells or DNA isolated thereof. Ge-
netic testing is currently the preferred method as it is fast, accurateand allows one to exclude maternal contamination of the fetal DNA.
To be eligible for prenatal or preimplantation genetic testing, howev-
er, the identity of the defective PEX gene and disease-causing muta-
tions in the index patient have to be known and preferably
conﬁrmed in the corresponding parental genes. When the defective
PEX gene and disease-causing mutations are unknown at the time of
prenatal testing, biochemical prenatal testing is the method of choice.
Biochemical prenatal testing for a PBD mostly involves measurement
of the activity of DHAP-AT in chorionic villus samples, cultured chori-
onic villus cells or cultured amniotic ﬂuid cells, immunoblot analysis
of peroxisomal thiolase (is processed after import in peroxisomes)
and determination of VLCFA concentrations in cultured chorionic
villous or amniotic ﬂuid cells. In addition, IF microscopy using anti-
bodies against catalase can be used in cultured chorionic villous or
amniotic ﬂuid cells to assess the presence of peroxisomes. Biochemi-
cal prenatal testing for a PBD is reliable and conclusive when the
index patient has a clear biochemical phenotype. For milder defects,
however, biochemical testing can be problematic and not always con-
clusive and thus genetic testing is preferred.
7.4. Genotype–phenotype correlations
ZSS disorders are autosomal recessive disorders that display
considerable clinical and genetic heterogeneity. Dependent on
their type and coding effect, mutations in any of the known PEX
genes can result in a severe early-lethal ZS clinical presentation, a
relatively mild IRD clinical presentation or an intermediate pheno-
type. Indeed, for most PEX genes mutations have been identiﬁed
that are associated with severe as well as other mutations that
are associated with less severe presentations. Although from the
clinical, biochemical, or cellular phenotype it is often not possible
to predict the defective PEX gene, there is in general a good corre-
lation between on the one hand the defective PEX gene and the
type of mutation and on the other hand the impact on peroxisome
assembly and function, and the clinical severity. Homozygosity or
compound heterozygosity for two severe mutations in any of the
12 PEX genes most commonly associated with a ZSS disorder will
invariably result in a severe biochemical and clinical phenotype.
Two mild mutations generally result in a milder biochemical and
clinical phenotype, although the outcome for such patients can be
variable due to secondary complications such as respiratory prob-
lems and infections that may severe the disease and can have
fatal consequences [108]. In addition, the course of disease in
milder patients often shows a progressive trend. Compound hetero-
zygosity for one mild and one severe mutation will result in an
intermediate biochemical and clinical phenotype with patients
even more susceptible for the negative consequences of secondary
complications.
8. Special cases
The availability of genetic testing for PEX genes and other
peroxisome-related genes in combination with improved laboratory
diagnostic tests including in particular microscopical assessment of
the peroxisomal phenotype in patient cells has resulted in the diagno-
sis of several patients at later ages, who previously had not been rec-
ognized. These patients are often relatively mildly affected and/or
show only a few of the symptoms that are typically associated with
ZSS disorders.
8.1. “Isolated” cerebellar ataxia
Two independent patients with cerebellar ataxia, axonal motor
neuropathy, and posterior column dysfunction but without mental
retardation [109] and a third patient with a similar phenotype, but
with cerebral white matter changes [110] were found by sequential
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chemically, their absolute plasma levels of VLCFA were normal with
a mild increased ratio of C26:0/C22:0. Plasma phytanic and pristanic
acid levels were elevated, as were the plasma levels of the bile acid in-
termediates DHCA and THCA and pipecolic acid, which suggested in-
volvement of multiple peroxisomal pathways. Biochemical studies in
cultured ﬁbroblasts of these patients revealed no abnormalities, and
the peroxisome appearance analyzed by catalase IF microscopy was
either normal or slightly mosaic. Culturing of the ﬁbroblasts at 40 °C
did not exacerbate the defect in peroxisome biogenesis.
A similar approach was used to identify the genetic defect in two
brothers with isolated progressive cerebellar ataxia [111]. Brain MRI
showed atrophy of the vermis and lateral hemispheres of the cerebel-
lum, but there were no signs of demyelination or neuronal migration
defects in forebrain and cerebellum in both patients. Biochemical anal-
ysis in plasma revealed a moderate increase of the bile acid
intermediates DHCA and THCA, and of phytanic and pristanic acid,
but normal levels of VLCFAs and pipecolic acid. Biochemical studies in
ﬁbroblasts showed only a slight decrease of the oxidation of phytanic
acid. Sequence analysis of the candidate genes PEX2, PEX10 and PEX12
revealed a homozygous nonsense mutation in the PEX2 gene as cause
for the isolated progressive cerebellar ataxia in these two brothers.
These cases indicate that a diagnosis of a PBD cannot always be
made or excluded based solely on the analysis of plasma VLCFA levels,
but that additional analyses are required, including the measurement
of the bile acid intermediates DHCA and THCA, which are probably
the best diagnostic predictors for a PBD.8.2. Clinical overlap with other syndromes
Several patients have been reported, who in fact showed clear per-
oxisomal biochemical aberrations, but because they initially were di-
agnosed with a different disease based on their clinical presentation,
they had not been examined for peroxisomal defects. For example,
Michelakakis et al. described a patient, who initially was diagnosed
with Leber congenital amaurosis (LCA) at the age of 6 months, but
was neurologically examined at the age of 2 years because of myo-
clonic seizures [112]. Based on the development of mild psychomotor
retardation with cerebellar tract involvement, mild facial dys-
morphism and mild demyelinating sensorimotor neuropathy, the ini-
tial diagnosis was questioned and metabolic studies were initiated,
which revealed a peroxisome biogenesis disorder due to homozygos-
ity of the p.G843D mutation in the PEX1 gene.
Very recently, a similar case was reported involving a 28-year cog-
nitively normal patient who was diagnosed with isolated LCA,
although the patient also showed sensorineural hearing loss and
Arnold-Chiari malformation [113]. After eliminating 500 common
mutations in 15 LCA genes, the patient's DNA was subjected to
whole exome sequencing which again identiﬁed the homozygous
p.G843D mutation in the PEX1 gene. Peroxisomal biochemical studies
subsequently conﬁrmed a ZSS disorder in the patient. Subsequent
screening of a cohort of LCA patients, revealed another 9 months old
baby with the same homozygous mutation, who at the age of
20 months was hospitalized for developmental delay, hypotonia and
seizures, and a diagnosis of ZSS was conﬁrmed.
These three cases consolidate the hypothesis of Ek and coworkers
already made in 1986 that some patients with LCA may turn out to
have a ZSS disorder [114].
Another example of a syndromewith clinical overlapwith ZSS disor-
ders is Usher syndrome, characterized by deafness and gradual
vision loss. Two unrelated patients, diagnosed with Usher syndrome
on the basis of sensorineural deafness and retinitis pigmentosa, turned
out to havemutations in the PEX6 gene, which in cells caused a relative-
ly mild peroxisomal biochemical dysfunction and peroxisomal mosai-
cism [115].8.3. Unusual peroxisomal phenotypes
An important aid in recognizing the possibility of a peroxisomal
disorder in patients, who only showminor or sometimes even normal
peroxisomal biochemical parameters, is the microscopical observa-
tion of the peroxisomal phenotype in cultured skin ﬁbroblasts of the
patients. As discussed above this also resulted in the identiﬁcation
of a novel class of peroxisomal defects affecting the division of perox-
isomes. The two patients currently known with a defect in peroxi-
some ﬁssion due to mutations in DLP1, also affecting mitochondrial
ﬁssion [18], and PEX11β [30] both only showed an aberrant peroxi-
somal phenotype while peroxisomal biochemical parameters were
essentially normal.
Another example of an unexpected peroxisomal phenotype was
recently reported in several patients with mutations in the PEX16
gene [52]. Before the identiﬁcation of these patients, mutations in
PEX16 were associated with a severe, lethal clinical presentation of a
ZSS disorder and ﬁbroblasts of patients displayed a defect in the
import of both peroxisomal matrix and membrane proteins.
The reported PEX16-defective patients, however, were moderately
affected and the biochemical parameters in ﬁbroblasts were only
mildly abnormal or even within the normal range. Catalase IF micros-
copy revealed the presence of import-competent peroxisomes, which
were increased in size but reduced in number [52].
8.4. Dominant mutations, digenic and oligogenic inheritance
So far, haplo insufﬁciency, dominant negative mutations or
digenic/oligogenic inheritance have not been reported for any of the
14 PEX genes associated with PBDs. The occurrence of haplo insufﬁ-
ciency, i.e. a single functional copy of a gene is insufﬁcient to maintain
normal function, seems unlikely because parents of diagnosed
patients, who are obligate carriers of one of the two mutations of
the patient, never show any clinical signs that could be related to
peroxisomal dysfunction.
Given the fact that most of the peroxins encoded by the PEX genes
have interactions with each other, it may be anticipated that exam-
ples of dominant negative mutations and/or digenic/oligogenic inher-
itance will be found in future. In the case of dominant-negative
mutations one would expect to ﬁnd only one heterozygous pathogen-
ic mutation in one of the PEX genes from a patient, while this muta-
tion is absent in the corresponding parental genes. In the case of
digenic or oligogenic inheritance, one may expect to ﬁnd heterozy-
gous pathogenic mutations in two (digenic) or more (oligogenic)
PEX genes that encode peroxins which interact with each other.
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